NCT00833326

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and docetaxel (with prophylactic growth factor support). Patients will receive increasing doses of study drug in combination with docetaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US will be enrolled in this study.

Conditions

• Advanced Cancer

Interventions

Type	Name	Description
DRUG	ARRY-334543, EGFR/ErbB2 inhibitor; oral	multiple dose, escalating
DRUG	Docetaxel, mitotic inhibitor; intravenous	multiple dose, single schedule
DRUG	Prophylactic growth factors; subcutaneous	standard of care

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2009-02-02
• Last updated: 2020-10-06

Locations

3 sites across 1 country: United States